NEWS

The department HTSR is well represented at the 17th ISPOR annual European Congress from 9-12 november in Amsterdam. Check the overview for posters, podium presentations and workshops.

For more information check the ISPOR program

1.

HEALTH ECONOMIC IMPACT OF VOLUME DOUBLING TIME AS BIOMARKER IN LUNG CANCER DIAGNOSIS

Brinkhof S, Siesling S, Groen, H and IJzerman M

2.

PATIENT PREFERENCES AND HIV DRUGS: WHAT ABOUT UNCERTAINTY?

Broekhuizen H, IJzerman M, Hauber AB, Groothuis-Oudshoorn CG

3.

A SYSTEMATIC REVIEW TO IDENTIFY THE USE OF PREFERENCE ELICITATION METHODS IN HEALTH CARE DECISION MAKING

Janus S, Weernink M, Til JA van, Manen JG van, Raisch DW and IJzerman MJ

4.

COMBINING HEADROOM AND RETURN ON INVESTMENT ANALYSIS TO RANK POTENTIAL COMMERCIAL VALUE OF SIX MEDICAL DEVICES IN DEVELOPMENT

Markiewicz K, Til JA van, Steuten LMG and IJzerman MJ

5.

BUDGET IMPACT ANALYSIS OF A RETURN-TO-WORK INTERVENTION FOR CANCER PATIENTS SHOWS HOSPITALS BEAR THE COSTS, FOR SOCIETY TO ENJOY THE BENEFITS

Mewes J, Steuten LMG, Boer A de, Frings-Desen M, IJzerman MJ and Harten Wvan

6.

PRIMARY TREATMENTS FOR INTERMEDIATE-RISK PROSTATE CANCER: A COST-EFFECTIVENESS AND VALUE-OFINFORMATION ANALYSIS

Piena M, IJzerman MJ and Steuten LMG

7.

COMPARISON OF THE VALUATION OF TREATMENT ALTERNATIVES IN PARKINSON'S DISEASE WITH BEST-WORST SCALING, TIME TRADE-OFF AND VISUAL ANALOGUE SCALES

Weernink M, Groothuis-Oudshoorn C, IJzerman MJ and Til JA van

8.

A VALIDATED PREDICTION MODEL AND NOMOGRAM FOR RISK OF RECURRENCE IN EARLY BREAST CANCER PATIENTS

Witteveen A, Vliegen IM, Siesling S and IJzerman MJ

9.

SURVIVAL AFTER LOCOREGIONAL RECURRENCE OR SECOND PRIMARY BREAST CANCER: IMPACT OF THE DISEASE-FREE INTERVAL

Witteveen A, Vliegen I, Sonke G, IJzerman M and Siesling S

10.

COST-EFFECTIVENESS ANALYSIS EVALUATING FACTOR VIII AS PRIMARY PROPHYLAXIS TREATMENT FOR PATIENTS WITH SEVERE HAEMOPHILIA A IN THE NETHERLANDS

Kip MMA, Van den Bosch M, Fischer K, Tamminga RYJ, Lepage-Nefkens I

Workshops:

F1 INTRODUCING THE ISPOR MCDA TASK FORCE: WHAT IS MCDA? WHAT ISN’T MCDA? HOW BEST TO USE IT IN HEALTH CARE DECISION MAKING?

IJzerman M, Devlin N, Thokala P and Marsh K

W17 DYNAMIC SIMULATION MODELING TO EVALUATE COMPLEX SYSTEM INTERVENTIONS FOR HEALTH CARE DELIVERY RESEARCH – WHAT METHODS FOR WHAT PROBLEMS?

Marshall D, Padula W, IJzerman M and Crown W

W19 USING MULTI-CRITERIA DECISION ANALYSIS TO EVALUATE THE POTENTIAL OF BIOSIMILARS TO LOWER COSTS IN ONCOLOGY

IJzerman M, Bennett C, Graaff M van der and Raisch DW

W29 SUPPORTING DECISION MAKING WITH MCDA: RECOMMENDATIONS FOR DEALING WITH UNCERTAINTY

IJzerman M, Marsh K, Groothuis CG and Broekhuizen H